Elsevier

Kidney International Reports

Volume 7, Issue 10, October 2022, Pages 2230-2241
Kidney International Reports

Clinical Research
Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients

https://doi.org/10.1016/j.ekir.2022.07.165Get rights and content
Under a Creative Commons license
open access

Introduction

Predicting the timing and occurrence of kidney replacement therapy (KRT), cardiovascular events, and death among patients with advanced chronic kidney disease (CKD) is clinically useful and relevant. We aimed to externally validate a recently developed CKD G4+ risk calculator for these outcomes and to assess its potential clinical impact in guiding vascular access placement.

Methods

We included 1517 patients from the European Quality (EQUAL) study, a European multicentre prospective cohort study of nephrology-referred advanced CKD patients aged ≥65 years. Model performance was assessed based on discrimination and calibration. Potential clinical utility for timing of referral for vascular access placement was studied with diagnostic measures and decision curve analysis (DCA).

Results

The model showed a good discrimination for KRT and “death after KRT,” with 2-year concordance (C) statistics of 0.74 and 0.76, respectively. Discrimination for cardiovascular events (2-year C-statistic: 0.70) and overall death (2-year C-statistic: 0.61) was poorer. Calibration was fairly accurate. Decision curves illustrated that using the model to guide vascular access referral would generally lead to less unused arteriovenous fistulas (AVFs) than following estimated glomerular filtration rate (eGFR) thresholds.

Conclusion

This study shows moderate to good predictive performance of the model in an older cohort of nephrology-referred patients with advanced CKD. Using the model to guide referral for vascular access placement has potential in combating unnecessary vascular surgeries.

Keywords

CKD
cardiovascular disease
death
external validation
kidney failure
prognostic model

Cited by (0)

12

Members of EQUAL study investigators are listed in the appendix.